GlassScriptPhysician profile
Dale Glenn Schaefer
NPI 1407895253
$1,000,675.48
in general payments reported to CMS, 2019-2025
45 companies · $201K in 2025
The $201K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242K · 2020: $60K · 2021: $86K · 2022: $140K · 2023: $122K · 2024: $150K · 2025: $201K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $274K · Consulting Fee: $118K · Travel and Lodging: $41K · Food and Beverage: $23K · Honoraria: $18K · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $273,721.25 |
| Consulting Fee | $117,800.00 |
| Travel and Lodging | $40,677.34 |
| Food and Beverage | $22,770.95 |
| Honoraria | $18,000.00 |
| Education | $465.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $339,177.94 | 2019-2025 | Otezla, Otezla |
| Abbvie INC. | $213,078.14 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Arcutis Biotherapeutics, INC. | $143,081.40 | 2023-2025 | Zoryve |
| Celgene Corporation | $103,420.10 | 2019 | |
| Janssen Biotech, INC. | $54,953.97 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $37,931.37 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $24,579.13 | 2022-2025 | Tremfya |
| Incyte Corporation | $23,735.70 | 2021-2025 | Opzelura |
| Organon LLC | $21,145.82 | 2023-2025 | Vtama, Hadlima, Nexplanon |
| Epi Health, LLC | $14,575.20 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10,551.58 | 2019-2024 | Cabtreo, Jublia, Duobrii |
| Dermavant Sciences, INC. | $2,852.99 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $1,662.93 | 2019-2025 | |
| Genzyme Corporation | $1,452.39 | 2019-2025 | |
| Ucb, INC. | $1,438.42 | 2019-2025 | Bimzelx, Cimzia |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,138.11 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $923.13 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $789.14 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $646.67 | 2019-2025 | Adbry |
| Almirall LLC | $473.68 | 2019-2025 | Seysara |
| Merz North America, INC. | $468.09 | 2020 | |
| Galderma Laboratories, L.P. | $448.48 | 2020-2025 | Nemluvio, Aklief |
| Vyne Pharmaceuticals INC. | $376.76 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $366.04 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $297.80 | 2019-2025 | |
| Journey Medical Corporation | $200.17 | 2020-2025 | |
| Fresenius Kabi USA, LLC | $194.01 | 2023-2024 | Idacio |
| Aclaris Therapeutics, INC. | $124.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.90 | 2023-2025 | Spevigo |
| Biofrontera INC. | $109.98 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $70.23 | 2025 | Sofdra |
| Dermira, INC. | $39.46 | 2020 | |
| Mimedx Group, INC. | $38.78 | 2024 | |
| Dusa Pharmaceuticals, INC. | $37.22 | 2019 | |
| Encore Dermatology INC. | $32.03 | 2020 | |
| Elekta, INC. | $23.93 | 2025 | Flexitron Hdr |
| Allergan, INC. | $22.39 | 2022 | |
| Merck Sharp & Dohme LLC | $17.91 | 2019 | |
| Kyowa Kirin, INC. | $15.99 | 2023 | Poteligeo |
| Medimetriks Pharmaceuticals, INC. | $15.12 | 2024 | Clindacin Etz |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.30 | 2021 | |
| Sebela Pharmaceuticals INC. | $12.37 | 2020 | |
| Pierre Fabre Pharmaceuticals, INC. | $4.62 | 2019 | |
| Prugen, INC. Pharmaceuticals | $2.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Schaefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.